HEADER IMMUNE SYSTEM 19-SEP-02 1H3V TITLE CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2,SG TITLE 2 P212121 CAVEAT 1H3V NAG D 1 HAS WRONG CHIRALITY AT ATOM C1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: IG GAMMA-1 CHAIN C REGION; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: CH2, CH3, RESIDUES 225-447; COMPND 5 SYNONYM: IGHG1 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606 KEYWDS IMMUNOGLOBULIN/FC-FRAGMENT, FC-FRAGMENT, GLYCOSYLATION, FCGR, KEYWDS 2 ANTIBODY, EFFECTOR FUNCTIONS, IMMUNE SYSTEM EXPDTA X-RAY DIFFRACTION AUTHOR S.KRAPP,Y.MIMURA,R.JEFFERIS,R.HUBER,P.SONDERMANN REVDAT 7 23-OCT-24 1H3V 1 REMARK REVDAT 6 13-DEC-23 1H3V 1 REMARK HETSYN REVDAT 5 29-JUL-20 1H3V 1 CAVEAT COMPND REMARK HETNAM REVDAT 5 2 1 LINK SITE ATOM REVDAT 4 19-OCT-11 1H3V 1 HEADER CAVEAT KEYWDS REMARK REVDAT 4 2 1 HET HETNAM HETSYN FORMUL REVDAT 4 3 1 LINK SITE HETATM VERSN REVDAT 3 24-FEB-09 1H3V 1 VERSN REVDAT 2 01-AUG-03 1H3V 1 REMARK HET FORMUL LINK REVDAT 2 2 1 ATOM TER HETATM CONECT REVDAT 1 23-JAN-03 1H3V 0 JRNL AUTH S.KRAPP,Y.MIMURA,R.JEFFERIS,R.HUBER,P.SONDERMANN JRNL TITL STRUCTURAL ANALYSIS OF HUMAN IGG-FC GLYCOFORMS REVEALS A JRNL TITL 2 CORRELATION BETWEEN GLYCOSYLATION AND STRUCTURAL INTEGRITY JRNL REF J.MOL.BIOL. V. 325 979 2003 JRNL REFN ISSN 0022-2836 JRNL PMID 12527303 JRNL DOI 10.1016/S0022-2836(02)01250-0 REMARK 2 REMARK 2 RESOLUTION. 3.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.0 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 82.8 REMARK 3 NUMBER OF REFLECTIONS : 7738 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.240 REMARK 3 FREE R VALUE : 0.314 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3317 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 192 REMARK 3 SOLVENT ATOMS : 91 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.500 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1H3V COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-SEP-02. REMARK 100 THE DEPOSITION ID IS D_1290011416. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-AUG-01 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 6.50 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : OS-MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 8183 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.100 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 82.8 REMARK 200 DATA REDUNDANCY : 2.000 REMARK 200 R MERGE (I) : 0.13000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : 81.8 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.38000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 1FC1 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.82 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: DIALYSIS AGAINST WATER, PH 6.50 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 24.73500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 70.87500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 40.42500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 70.87500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 24.73500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 40.42500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 7660 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 21180 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 51.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 THR A 225 REMARK 465 CYS A 226 REMARK 465 PRO A 227 REMARK 465 PRO A 228 REMARK 465 CYS A 229 REMARK 465 PRO A 230 REMARK 465 ALA A 231 REMARK 465 PRO A 232 REMARK 465 GLU A 233 REMARK 465 LEU A 234 REMARK 465 LEU A 235 REMARK 465 GLY A 236 REMARK 465 GLY A 237 REMARK 465 GLY A 446 REMARK 465 LYS A 447 REMARK 465 THR B 225 REMARK 465 CYS B 226 REMARK 465 PRO B 227 REMARK 465 PRO B 228 REMARK 465 CYS B 229 REMARK 465 PRO B 230 REMARK 465 ALA B 231 REMARK 465 PRO B 232 REMARK 465 GLU B 233 REMARK 465 LEU B 234 REMARK 465 LEU B 235 REMARK 465 GLY B 236 REMARK 465 GLY B 237 REMARK 465 PRO B 445 REMARK 465 GLY B 446 REMARK 465 LYS B 447 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 SER A 444 OG REMARK 470 PRO A 445 CA C O CB CG CD REMARK 470 SER B 444 CA C O CB OG REMARK 475 REMARK 475 ZERO OCCUPANCY RESIDUES REMARK 475 THE FOLLOWING RESIDUES WERE MODELED WITH ZERO OCCUPANCY. REMARK 475 THE LOCATION AND PROPERTIES OF THESE RESIDUES MAY NOT REMARK 475 BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 475 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE) REMARK 475 M RES C SSEQI REMARK 475 HIS B 285 REMARK 475 ASN B 297 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLU A 269 CD OE1 OE2 REMARK 480 LYS A 290 CD CE NZ REMARK 480 GLN A 294 CB CG REMARK 480 GLN A 295 CB CG CD OE1 NE2 REMARK 480 TYR A 296 CB CG CD1 CD2 CE1 CE2 CZ REMARK 480 TYR A 296 OH REMARK 480 LYS A 317 NZ REMARK 480 ILE A 332 CG1 CD1 REMARK 480 SER A 383 C O REMARK 480 GLN A 386 CB CG CD OE1 NE2 REMARK 480 LYS A 414 CB CG CD CE NZ REMARK 480 GLN A 419 CG REMARK 480 VAL A 422 CG2 REMARK 480 SER A 424 CB OG REMARK 480 SER A 442 C O REMARK 480 LEU A 443 CG CD1 CD2 REMARK 480 LEU B 242 CD1 REMARK 480 LYS B 246 CG CD CE NZ REMARK 480 ILE B 253 CD1 REMARK 480 VAL B 266 CG1 REMARK 480 SER B 267 CB OG REMARK 480 GLU B 269 CB CG CD OE1 OE2 REMARK 480 ASP B 270 CB CG OD1 OD2 REMARK 480 PRO B 271 C O REMARK 480 VAL B 273 CG1 REMARK 480 LYS B 274 CB CG CD CE NZ REMARK 480 TYR B 278 CB CG CD1 CD2 REMARK 480 VAL B 279 CB CG1 CG2 REMARK 480 VAL B 284 CB CG1 CG2 REMARK 480 ASN B 286 CB CG OD1 ND2 REMARK 480 ALA B 287 CB REMARK 480 LYS B 288 CB CG CD CE NZ REMARK 480 THR B 289 CG2 REMARK 480 LYS B 290 C O REMARK 480 PRO B 291 C O REMARK 480 GLN B 294 CD OE1 NE2 REMARK 480 GLN B 295 CG CD OE1 NE2 REMARK 480 TYR B 296 CD1 CD2 CE1 CE2 CZ OH REMARK 480 SER B 298 C O REMARK 480 TYR B 300 CB CG CD1 CD2 CE1 CE2 CZ REMARK 480 TYR B 300 OH REMARK 480 ASN B 325 CA C O CB CG OD1 ND2 REMARK 480 LYS B 326 CG CD CE NZ REMARK 480 LEU B 328 O REMARK 480 ALA B 330 O REMARK 480 PRO B 331 C O REMARK 480 GLU B 333 C O CB CG CD OE1 OE2 REMARK 480 SER B 337 CB OG REMARK 480 ARG B 355 CB CG CD NE CZ NH1 NH2 REMARK 480 SER B 383 CB OG REMARK 480 ASN B 384 CG OD1 ND2 REMARK 480 VAL B 422 CG2 REMARK 480 LEU B 432 CD1 REMARK 480 SER B 440 OG REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HIS A 433 N HIS A 435 1.85 REMARK 500 O HIS B 433 N HIS B 435 1.88 REMARK 500 O LEU A 441 O HOH A 2047 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 CYS A 367 CA - CB - SG ANGL. DEV. = 6.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 270 67.59 -174.66 REMARK 500 ASN A 286 158.69 -29.04 REMARK 500 ALA A 287 -86.17 -146.49 REMARK 500 LYS A 290 114.38 -171.66 REMARK 500 GLN A 294 124.56 -177.40 REMARK 500 TYR A 296 -124.02 -122.96 REMARK 500 SER A 298 -0.36 154.29 REMARK 500 THR A 299 -165.56 -116.93 REMARK 500 GLU A 356 -13.41 -48.40 REMARK 500 PRO A 374 -171.14 -67.40 REMARK 500 ASN A 384 77.12 -21.69 REMARK 500 PRO A 387 -172.95 -62.78 REMARK 500 ALA A 431 25.39 -75.53 REMARK 500 HIS A 433 -140.03 -64.64 REMARK 500 ASN A 434 17.90 -33.69 REMARK 500 HIS A 435 37.36 71.29 REMARK 500 TYR A 436 126.01 -179.53 REMARK 500 SER A 444 169.16 155.58 REMARK 500 GLU B 269 0.68 -68.24 REMARK 500 ASP B 270 79.30 172.04 REMARK 500 GLN B 283 59.67 70.89 REMARK 500 ASN B 286 164.99 -38.48 REMARK 500 ALA B 287 -86.23 -149.51 REMARK 500 LYS B 290 112.39 -173.77 REMARK 500 GLN B 294 111.00 -176.18 REMARK 500 TYR B 296 -126.10 -127.47 REMARK 500 SER B 298 2.69 152.93 REMARK 500 THR B 299 -167.77 -114.85 REMARK 500 PRO B 374 -164.28 -67.22 REMARK 500 ASN B 384 68.26 -4.73 REMARK 500 PRO B 387 -179.94 -54.38 REMARK 500 HIS B 433 -178.71 -59.70 REMARK 500 ASN B 434 16.45 10.34 REMARK 500 TYR B 436 132.28 -170.46 REMARK 500 SER B 442 144.98 -172.22 REMARK 500 REMARK 500 REMARK: NULL REMARK 615 REMARK 615 ZERO OCCUPANCY ATOM REMARK 615 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 615 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 615 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 615 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 615 M RES C SSEQI REMARK 615 NAG D 1 REMARK 615 NAG D 2 REMARK 615 BMA D 3 REMARK 615 BMA D 4 REMARK 615 NAG D 5 REMARK 615 GAL D 6 REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1H3U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (M3N2F)2 REMARK 900 RELATED ID: 1H3T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT, GLYCOFORM (MN2F)2 REMARK 900 RELATED ID: 1H3W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2, REMARK 900 SG C2221 REMARK 900 RELATED ID: 1H3X RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G0F)2 REMARK 900 RELATED ID: 1H3Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN IGG1 FC FRAGMENT, HIGH SALT CONDITION REMARK 900 RELATED ID: 1AJ7 RELATED DB: PDB REMARK 900 IMMUNOGLOBULIN 48G7 GERMLINE FAB ANTIBODY COMPLEXED WITH HAPTEN 5- REMARK 900 (PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID. AFFINITY MATURATION REMARK 900 OF AN ESTEROLYTIC ANTIBODY REMARK 900 RELATED ID: 1D5B RELATED DB: PDB REMARK 900 UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY REMARK 900 RELATED ID: 1D5I RELATED DB: PDB REMARK 900 UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY REMARK 900 RELATED ID: 1D6V RELATED DB: PDB REMARK 900 CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE REMARK 900 ANTIBODY MATURATION REMARK 900 RELATED ID: 1DN2 RELATED DB: PDB REMARK 900 FC FRAGMENT OF HUMAN IGG1 IN COMPLEX WITH AN ENGINEERED 13 RESIDUE REMARK 900 PEPTIDE DCAWHLGELVWCT-NH2 REMARK 900 RELATED ID: 1E4K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF SOLUBLE HUMAN IGG1 FC FRAGMENT-FC-GAMMA REMARK 900 RECEPTOR III COMPLEX REMARK 900 RELATED ID: 1FC1 RELATED DB: PDB REMARK 900 FC FRAGMENT (IGG1 CLASS) REMARK 900 RELATED ID: 1FC2 RELATED DB: PDB REMARK 900 RELATED ID: 1FCC RELATED DB: PDB REMARK 900 RELATED ID: 1HZH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROADAND POTENT REMARK 900 ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: ATEMPLATE FOR HIV VACCINE REMARK 900 DESIGN REMARK 900 RELATED ID: 1I7Z RELATED DB: PDB REMARK 900 ANTIBODY GNC92H2 BOUND TO LIGAND REMARK 900 RELATED ID: 1IIS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FCG RECEPTOR IN COMPLEX WITHAN FC REMARK 900 FRAGMENT OF IGG1 ( ORTHORHOMBIC) REMARK 900 RELATED ID: 1IIX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FCG RECEPTOR IN COMPLEX WITHAN FC REMARK 900 FRAGMENT OF IGG1 ( HEXAGONAL) REMARK 900 RELATED ID: 2RCS RELATED DB: PDB REMARK 900 IMMUNOGLOBULIN 48G7 GERMLINE FAB - AFFINITY MATURATION OF AN REMARK 900 ESTEROLYTIC ANTIBODY REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE PRIMARY SEQUENCE FOR THIS ENTRY IS VERY SIMILAR TO REMARK 999 SWISSPROT ENTRY P01857 (GC1_HUMAN) WITH 96% SEQUENCE REMARK 999 IDENTITY. DBREF 1H3V A 225 447 PDB 1H3V 1H3V 225 447 DBREF 1H3V B 225 447 PDB 1H3V 1H3V 225 447 SEQRES 1 A 223 THR CYS PRO PRO CYS PRO ALA PRO GLU LEU LEU GLY GLY SEQRES 2 A 223 PRO SER VAL PHE LEU PHE PRO PRO LYS PRO LYS ASP THR SEQRES 3 A 223 LEU MET ILE SER ARG THR PRO GLU VAL THR CYS VAL VAL SEQRES 4 A 223 VAL ASP VAL SER HIS GLU ASP PRO GLN VAL LYS PHE ASN SEQRES 5 A 223 TRP TYR VAL ASP GLY VAL GLN VAL HIS ASN ALA LYS THR SEQRES 6 A 223 LYS PRO ARG GLU GLN GLN TYR ASN SER THR TYR ARG VAL SEQRES 7 A 223 VAL SER VAL LEU THR VAL LEU HIS GLN ASN TRP LEU ASP SEQRES 8 A 223 GLY LYS GLU TYR LYS CYS LYS VAL SER ASN LYS ALA LEU SEQRES 9 A 223 PRO ALA PRO ILE GLU LYS THR ILE SER LYS ALA LYS GLY SEQRES 10 A 223 GLN PRO ARG GLU PRO GLN VAL TYR THR LEU PRO PRO SER SEQRES 11 A 223 ARG GLU GLU MET THR LYS ASN GLN VAL SER LEU THR CYS SEQRES 12 A 223 LEU VAL LYS GLY PHE TYR PRO SER ASP ILE ALA VAL GLU SEQRES 13 A 223 TRP GLU SER ASN GLY GLN PRO GLU ASN ASN TYR LYS THR SEQRES 14 A 223 THR PRO PRO VAL LEU ASP SER ASP GLY SER PHE PHE LEU SEQRES 15 A 223 TYR SER LYS LEU THR VAL ASP LYS SER ARG TRP GLN GLN SEQRES 16 A 223 GLY ASN VAL PHE SER CYS SER VAL MET HIS GLU ALA LEU SEQRES 17 A 223 HIS ASN HIS TYR THR GLN LYS SER LEU SER LEU SER PRO SEQRES 18 A 223 GLY LYS SEQRES 1 B 223 THR CYS PRO PRO CYS PRO ALA PRO GLU LEU LEU GLY GLY SEQRES 2 B 223 PRO SER VAL PHE LEU PHE PRO PRO LYS PRO LYS ASP THR SEQRES 3 B 223 LEU MET ILE SER ARG THR PRO GLU VAL THR CYS VAL VAL SEQRES 4 B 223 VAL ASP VAL SER HIS GLU ASP PRO GLN VAL LYS PHE ASN SEQRES 5 B 223 TRP TYR VAL ASP GLY VAL GLN VAL HIS ASN ALA LYS THR SEQRES 6 B 223 LYS PRO ARG GLU GLN GLN TYR ASN SER THR TYR ARG VAL SEQRES 7 B 223 VAL SER VAL LEU THR VAL LEU HIS GLN ASN TRP LEU ASP SEQRES 8 B 223 GLY LYS GLU TYR LYS CYS LYS VAL SER ASN LYS ALA LEU SEQRES 9 B 223 PRO ALA PRO ILE GLU LYS THR ILE SER LYS ALA LYS GLY SEQRES 10 B 223 GLN PRO ARG GLU PRO GLN VAL TYR THR LEU PRO PRO SER SEQRES 11 B 223 ARG GLU GLU MET THR LYS ASN GLN VAL SER LEU THR CYS SEQRES 12 B 223 LEU VAL LYS GLY PHE TYR PRO SER ASP ILE ALA VAL GLU SEQRES 13 B 223 TRP GLU SER ASN GLY GLN PRO GLU ASN ASN TYR LYS THR SEQRES 14 B 223 THR PRO PRO VAL LEU ASP SER ASP GLY SER PHE PHE LEU SEQRES 15 B 223 TYR SER LYS LEU THR VAL ASP LYS SER ARG TRP GLN GLN SEQRES 16 B 223 GLY ASN VAL PHE SER CYS SER VAL MET HIS GLU ALA LEU SEQRES 17 B 223 HIS ASN HIS TYR THR GLN LYS SER LEU SER LEU SER PRO SEQRES 18 B 223 GLY LYS MODRES 1H3V ASN A 297 ASN GLYCOSYLATION SITE MODRES 1H3V ASN B 297 ASN GLYCOSYLATION SITE HET NAG C 1 14 HET NAG C 2 14 HET BMA C 3 11 HET MAN C 4 11 HET NAG C 5 14 HET GAL C 6 11 HET MAN C 7 11 HET FUL C 8 10 HET NAG D 1 14 HET NAG D 2 14 HET BMA D 3 11 HET BMA D 4 11 HET NAG D 5 14 HET GAL D 6 11 HET MAN D 7 11 HET FUL D 8 10 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM BMA BETA-D-MANNOPYRANOSE HETNAM MAN ALPHA-D-MANNOPYRANOSE HETNAM GAL BETA-D-GALACTOPYRANOSE HETNAM FUL BETA-L-FUCOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN BMA BETA-D-MANNOSE; D-MANNOSE; MANNOSE HETSYN MAN ALPHA-D-MANNOSE; D-MANNOSE; MANNOSE HETSYN GAL BETA-D-GALACTOSE; D-GALACTOSE; GALACTOSE HETSYN FUL BETA-L-FUCOSE; 6-DEOXY-BETA-L-GALACTOPYRANOSE; L- HETSYN 2 FUL FUCOSE; FUCOSE; 6-DEOXY-BETA-L-GALACTOSE FORMUL 3 NAG 6(C8 H15 N O6) FORMUL 3 BMA 3(C6 H12 O6) FORMUL 3 MAN 3(C6 H12 O6) FORMUL 3 GAL 2(C6 H12 O6) FORMUL 3 FUL 2(C6 H12 O5) FORMUL 5 HOH *91(H2 O) HELIX 1 1 LYS A 246 MET A 252 1 7 HELIX 2 2 LEU A 309 ASP A 315 1 7 HELIX 3 3 SER A 354 MET A 358 5 5 HELIX 4 4 LYS A 414 GLN A 419 1 6 HELIX 5 5 LYS B 246 MET B 252 1 7 HELIX 6 6 LEU B 309 ASP B 315 1 7 HELIX 7 7 SER B 354 LYS B 360 5 7 HELIX 8 8 LYS B 414 GLN B 419 1 6 HELIX 9 9 LEU B 432 TYR B 436 5 5 SHEET 1 AA 4 SER A 239 PHE A 243 0 SHEET 2 AA 4 GLU A 258 VAL A 264 -1 O THR A 260 N PHE A 243 SHEET 3 AA 4 VAL A 302 THR A 307 -1 O VAL A 302 N VAL A 263 SHEET 4 AA 4 THR A 289 ARG A 292 -1 O LYS A 290 N VAL A 305 SHEET 1 AB 3 TRP A 277 VAL A 279 0 SHEET 2 AB 3 TYR A 319 VAL A 323 -1 O LYS A 320 N TYR A 278 SHEET 3 AB 3 ILE A 332 ILE A 336 -1 O ILE A 332 N VAL A 323 SHEET 1 AC 4 GLN A 347 LEU A 351 0 SHEET 2 AC 4 GLN A 362 PHE A 372 -1 O THR A 366 N LEU A 351 SHEET 3 AC 4 PHE A 404 ASP A 413 -1 O PHE A 404 N PHE A 372 SHEET 4 AC 4 TYR A 391 THR A 393 -1 O LYS A 392 N LYS A 409 SHEET 1 AD 4 GLN A 347 LEU A 351 0 SHEET 2 AD 4 GLN A 362 PHE A 372 -1 O THR A 366 N LEU A 351 SHEET 3 AD 4 PHE A 404 ASP A 413 -1 O PHE A 404 N PHE A 372 SHEET 4 AD 4 VAL A 397 LEU A 398 -1 O VAL A 397 N PHE A 405 SHEET 1 AE 3 ALA A 378 GLU A 382 0 SHEET 2 AE 3 PHE A 423 MET A 428 -1 O SER A 424 N GLU A 382 SHEET 3 AE 3 THR A 437 LEU A 441 -1 O THR A 437 N VAL A 427 SHEET 1 BA 4 SER B 239 PHE B 243 0 SHEET 2 BA 4 GLU B 258 VAL B 264 -1 O THR B 260 N PHE B 243 SHEET 3 BA 4 VAL B 302 THR B 307 -1 O VAL B 302 N VAL B 263 SHEET 4 BA 4 THR B 289 ARG B 292 -1 O LYS B 290 N VAL B 305 SHEET 1 BB 3 TRP B 277 VAL B 279 0 SHEET 2 BB 3 TYR B 319 VAL B 323 -1 O LYS B 320 N TYR B 278 SHEET 3 BB 3 ILE B 332 ILE B 336 -1 O ILE B 332 N VAL B 323 SHEET 1 BC 4 GLN B 347 LEU B 351 0 SHEET 2 BC 4 GLN B 362 PHE B 372 -1 O THR B 366 N LEU B 351 SHEET 3 BC 4 PHE B 404 ASP B 413 -1 O PHE B 404 N PHE B 372 SHEET 4 BC 4 TYR B 391 THR B 393 -1 O LYS B 392 N LYS B 409 SHEET 1 BD 4 GLN B 347 LEU B 351 0 SHEET 2 BD 4 GLN B 362 PHE B 372 -1 O THR B 366 N LEU B 351 SHEET 3 BD 4 PHE B 404 ASP B 413 -1 O PHE B 404 N PHE B 372 SHEET 4 BD 4 VAL B 397 LEU B 398 -1 O VAL B 397 N PHE B 405 SHEET 1 BE 4 GLN B 386 PRO B 387 0 SHEET 2 BE 4 ALA B 378 SER B 383 -1 O SER B 383 N GLN B 386 SHEET 3 BE 4 PHE B 423 MET B 428 -1 O SER B 424 N GLU B 382 SHEET 4 BE 4 THR B 437 LEU B 441 -1 O THR B 437 N VAL B 427 SSBOND 1 CYS A 261 CYS A 321 1555 1555 2.03 SSBOND 2 CYS A 367 CYS A 425 1555 1555 2.03 SSBOND 3 CYS B 261 CYS B 321 1555 1555 2.04 SSBOND 4 CYS B 367 CYS B 425 1555 1555 2.03 LINK ND2 ASN A 297 C1 NAG C 1 1555 1555 1.45 LINK ND2 ASN B 297 C1 NAG D 1 1555 1555 1.46 LINK O4 NAG C 1 C1 NAG C 2 1555 1555 1.38 LINK O6 NAG C 1 C1 FUL C 8 1555 1555 1.41 LINK O4 NAG C 2 C1 BMA C 3 1555 1555 1.40 LINK O6 BMA C 3 C1 MAN C 4 1555 1555 1.39 LINK O3 BMA C 3 C1 MAN C 7 1555 1555 1.39 LINK O2 MAN C 4 C1 NAG C 5 1555 1555 1.37 LINK O4 NAG C 5 C1 GAL C 6 1555 1555 1.39 LINK O4 NAG D 1 C1 NAG D 2 1555 1555 1.40 LINK O6 NAG D 1 C1 FUL D 8 1555 1555 1.42 LINK O4 NAG D 2 C1 BMA D 3 1555 1555 1.40 LINK O6 BMA D 3 C1 BMA D 4 1555 1555 1.41 LINK O3 BMA D 3 C1 MAN D 7 1555 1555 1.40 LINK O2 BMA D 4 C1 NAG D 5 1555 1555 1.38 LINK O4 NAG D 5 C1 GAL D 6 1555 1555 1.39 CISPEP 1 TYR A 373 PRO A 374 0 0.32 CISPEP 2 TYR B 373 PRO B 374 0 0.28 CRYST1 49.470 80.850 141.750 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020214 0.000000 0.000000 0.00000 SCALE2 0.000000 0.012368 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007055 0.00000